Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at Guggenheim

Share on StockTwits

Guggenheim began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Monday, September 17th, The Fly reports. The brokerage issued a buy rating on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on ADAP. BidaskClub downgraded Adaptimmune Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 4th. ValuEngine raised Adaptimmune Therapeutics from a buy rating to a strong-buy rating in a research report on Monday, July 2nd. Cowen reissued a buy rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, July 18th. TheStreet cut Adaptimmune Therapeutics from a c- rating to a d+ rating in a research report on Monday, July 16th. Finally, Leerink Swann increased their price target on Adaptimmune Therapeutics to $20.00 and gave the company an outperform rating in a research report on Monday, June 4th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $19.33.

Shares of Adaptimmune Therapeutics stock traded down $0.20 during trading hours on Monday, hitting $12.41. The company’s stock had a trading volume of 466,897 shares, compared to its average volume of 496,185. Adaptimmune Therapeutics has a 12 month low of $6.60 and a 12 month high of $14.63. The company has a market capitalization of $1.28 billion, a P/E ratio of -15.51 and a beta of 1.06.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.20). Adaptimmune Therapeutics had a negative return on equity of 47.22% and a negative net margin of 191.14%. The business had revenue of $9.04 million during the quarter, compared to the consensus estimate of $7.76 million. On average, equities research analysts expect that Adaptimmune Therapeutics will post -1.02 EPS for the current fiscal year.

In other Adaptimmune Therapeutics news, Director Ali Behbahani acquired 12,000,000 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was bought at an average cost of $1.67 per share, with a total value of $20,040,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total value of $256,250.00. The disclosure for this sale can be found here. Company insiders own 26.47% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $122,000. BB&T Securities LLC acquired a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $128,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of Adaptimmune Therapeutics by 70.0% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,951 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 13,151 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Adaptimmune Therapeutics in the first quarter valued at approximately $168,000. Finally, Trexquant Investment LP acquired a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $178,000. 59.32% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Further Reading: Buyback For Investors Defined

The Fly

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.